Evaluation and management of headache in primary care.

Abstract:

:Headache disorders are ubiquitous, common, disabling and to a very large extent treatable in primary care. In this review, the important headache disorders are described together with their impact on public health. Suggestions are set out for their optimal management, although many of these are necessarily based more on expert opinion than on formal evidence, since clinical trials have covered only narrow areas of headache treatment. Most people whose lives are adversely affected by headache disorders benefit from drug interventions, either acute or preventative, but other forms of treatment are always important and should never be overlooked. An important disorder is entirely iatrogenic: its recognition is crucial to its effective management, which requires medication withdrawal. Future research is needed not only into the mechanisms of headache causation, as a prerequisite for the development of better treatments, but also into public health aspects seeking an explanation of (and remedy for) the low priority given worldwide to headache-related healthcare despite the severe human and socioeconomic consequences.

journal_name

Expert Rev Neurother

authors

Steiner TJ

doi

10.1586/14737175.4.3.425

keywords:

subject

Has Abstract

pub_date

2004-05-01 00:00:00

pages

425-37

issue

3

eissn

1473-7175

issn

1744-8360

journal_volume

4

pub_type

杂志文章,评审
  • Interventions to promote the evidence-based care of children with ADHD in primary-care settings.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a commonly occurring behavioral disorder among children. Community-based physicians are often the primary providers of services for children with ADHD. A set of consensus guidelines has been published by the American Academy of Pediatrics that provides best-practice d...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.5

    authors: Langberg JM,Brinkman WB,Lichtenstein PK,Epstein JN

    更新日期:2009-04-01 00:00:00

  • Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.

    abstract::Clomipramine ushered in a new age of pharmacotherapy for obsessive-compulsive disorders, and it also facilitated our understanding of the biological aspects of obsessive-compulsive disorder, focusing on the serotonergic systems. The introduction of selective serotonin reuptake inhibitors has led to great progress in t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.7.945

    authors: Kamijima K,Aoki M

    更新日期:2006-07-01 00:00:00

  • Update on the treatment of vitamin B6 dependent epilepsies.

    abstract::Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1648212

    authors: Mastrangelo M,Cesario S

    更新日期:2019-11-01 00:00:00

  • Memory problems in dementia: adaptation and coping strategies and psychosocial treatments.

    abstract::Memory problems are generally quite prominent in dementia and they have a significant impact on everyday functioning. Medication developed for Alzheimer's disease, for example, acetylcholinesterase inhibitors, can slow down the increase of cognitive impairment for a while. In addition to pharmacotherapy, psychosocial ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.167

    authors: Dröes RM,van der Roest HG,van Mierlo L,Meiland FJ

    更新日期:2011-12-01 00:00:00

  • Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.

    abstract::The most successful approach for treating people with Alzheimer's disease to date has been by improving cholinergic transmission using cholinesterase inhibitors. Many of these drugs selectively inhibit acetylcholinesterase but some agents inhibit both acetylcholinesterase and butyrylcholinesterase. Recent evidence fro...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.5.1.101

    authors: Tasker A,Perry EK,Ballard CG

    更新日期:2005-01-01 00:00:00

  • Fingolimod for the treatment of relapsing multiple sclerosis.

    abstract::Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of l...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.193

    authors: Jeffery DR,Markowitz CE,Reder AT,Weinstock-Guttman B,Tobias K

    更新日期:2011-02-01 00:00:00

  • Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease.

    abstract::Divalproex sodium has been widely use for the treatment of bipolar disorder, behavioral control in schizophrenia, seizure and agitation in Alzheimer's disease. With the advent of other mood stabilizers and anticonvulsants, the use of divaplroex sodium has been slightly decreased; however, it has been a major mediation...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章

    doi:10.1586/ern.11.194

    authors: Han C,Shim DS,Lee SJ,Patkar AA,Masand PS,Pae CU

    更新日期:2012-02-01 00:00:00

  • No evidence of disease activity in multiple sclerosis patients.

    abstract:INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1202763

    authors: Matta AP,Nascimento OJ,Ferreira AC,Magalhães TN,Benevides TP,Kirmse A,Dib JG,Cal H,Orsini M,Araujo LM

    更新日期:2016-11-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00

  • Light and chemical control of neuronal circuits: possible applications in neurotherapy.

    abstract::Millions of people worldwide suffer from diseases that result from a failure of central pathways to regulate behavioral and physiological processes. Advances in genetics and pharmacology have already allowed us to appreciate that rather than this dysregulation being systemic throughout the brain, it is usually rooted ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.948850

    authors: Whittle AJ,Walsh J,de Lecea L

    更新日期:2014-09-01 00:00:00

  • Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.

    abstract::Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with MS and their DMD exposure in four Canadian provinces. Methods: We i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1847085

    authors: Ng HS,Zhu F,Kingwell E,Zhao Y,Yao S,Ekuma O,Svenson LW,Evans C,Fisk JD,Marrie RA,Tremlett H

    更新日期:2021-01-01 00:00:00

  • Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?

    abstract::Braak's proposal that, in patients with Parkinson's disease, Lewy bodies and neurites progressively invade the brain through regions connected to autonomic and olfactory centers remains contentious. Confounding factors include the lack of an in vivo marker to examine the progression of Lewy pathology, the retrospectiv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.47

    authors: Halliday G,McCann H,Shepherd C

    更新日期:2012-06-01 00:00:00

  • The role of electroencephalogram in neonatal seizure detection.

    abstract:INTRODUCTION:The role of EEG in neonatal seizure detection is well-established, being the multichannel video-EEG the gold standard. However, in the clinical practice often amplitude integrated EEG (aEEG) is used, in order to overcome the difficulties related to EEG use. Areas covered: An overview regarding neonatal sei...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2018.1413352

    authors: Pisani F,Pavlidis E

    更新日期:2018-02-01 00:00:00

  • Precision medicine in genetic epilepsies: break of dawn?

    abstract:INTRODUCTION:Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1253476

    authors: Reif PS,Tsai MH,Helbig I,Rosenow F,Klein KM

    更新日期:2017-04-01 00:00:00

  • Anaplastic astrocytomas: biology and treatment.

    abstract::Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms. Currently, the only factors that have been shown to influence prognosis in patients with AA are age and Karnofsky performance status. Attempts have been made to identify biological prognostic factors for response to therapy an...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.8.4.575

    authors: Chamberlain MC,Chowdhary SA,Glantz MJ

    更新日期:2008-04-01 00:00:00

  • Treatment of chronic inflammatory demyelinating polyneuropathy.

    abstract::Chronic inflammatory demyelinating polyradiculoneuropathy is a neuromuscular disorder for which immunological factors are undoubtedly important in the etiopathogenesis. As clinical recognition of this disorder has improved, immunosuppressive and immunomodulating treatments have emerged as the treatments of choice and ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.2.233

    authors: Kaplan RL,Albers JW

    更新日期:2003-03-01 00:00:00

  • Muscle trigger point therapy in tension-type headache.

    abstract::Recent evidence suggests that active trigger points (TrPs) in neck and shoulder muscles contribute to tension-type headache. Active TrPs within the suboccipital, upper trapezius, sternocleidomastoid, temporalis, superior oblique and lateral rectus muscles have been associated with chronic and episodic tension-type hea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.138

    authors: Alonso-Blanco C,de-la-Llave-Rincón AI,Fernández-de-las-Peñas C

    更新日期:2012-03-01 00:00:00

  • Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.

    abstract:INTRODUCTION:Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious and safe treatments. In this scenario, drugs targeting GCRP, monoclo...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1772758

    authors: De Matteis E,Guglielmetti M,Ornello R,Spuntarelli V,Martelletti P,Sacco S

    更新日期:2020-06-01 00:00:00

  • Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.

    abstract::With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.3.357

    authors: Bergamaschi R

    更新日期:2006-03-01 00:00:00

  • What happens when natalizumab therapy is stopped?

    abstract::Natalizumab is an α-4 integrin antagonist used for the treatment of relapsing multiple sclerosis (MS). Concerns with the drug have a risen owing to a heightened risk of progressive multifocal leukoencephalopathy, which has caused some physicians to interrupt or stop treatment altogether. The article under review evalu...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章

    doi:10.1586/ern.11.109

    authors: Schaaf SM,Pitt D,Racke MK

    更新日期:2011-09-01 00:00:00

  • Cannabinoids as potential new therapy for the treatment of gliomas.

    abstract::Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6-12 months. The development of new the...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.1.37

    authors: Parolaro D,Massi P

    更新日期:2008-01-01 00:00:00

  • Response of gait deficits to neuromuscular electrical stimulation for stroke survivors.

    abstract::Persistent gait deficits after stroke can cause falls, elevated energy cost and poor endurance. Coordination impairment is an underlying cause of gait deficits. Few efficacious interventions have been described that have targeted and measured restoration of coordinated gait components. Neuromuscular electrical stimula...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.10.1511

    authors: Daly JJ

    更新日期:2006-10-01 00:00:00

  • Cognitive-behavioral therapy for bipolar disorder.

    abstract::Bipolar disorder is one of the most serious and prevalent psychiatric disorders. The aim of the present article is to review the efficiency of cognitive-behavioral therapy (CBT) for bipolar patients. Some studies show consistent evidence that cognitive therapy, concomitant to psycho-education and pharmacological treat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.75

    authors: da Costa RT,Rangé BP,Malagris LE,Sardinha A,de Carvalho MR,Nardi AE

    更新日期:2010-07-01 00:00:00

  • Retinoic acid as a therapeutic option in Alzheimer's disease: a focus on cholinergic restoration.

    abstract::Retinoic acid is a potent cell differentiating factor, which through its nuclear receptors affects a vast range of promoter sites in brain neuronal and glial cells in every step of embryonic and postnatal life. Its capacities, facilitating maturation of neurotransmitter phenotype in different groups of neurons, pave t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1008456

    authors: Szutowicz A,Bielarczyk H,Jankowska-Kulawy A,Ronowska A,Pawełczyk T

    更新日期:2015-03-01 00:00:00

  • Use of antiepileptic drugs in pregnancy.

    abstract::Babies born to mothers exposed to antiepileptic drugs (AEDs) are at increased risk for major congenital malformations, cognitive impairment and fetal death. For the millions of women with epilepsy, maintaining the safest drug that will successfully prevent seizures during pregnancy remains a primary consideration. The...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.7.1077

    authors: Tatum WO

    更新日期:2006-07-01 00:00:00

  • Cognitive and behavioral assessment in Parkinson's disease.

    abstract::Introduction: Cognitive impairment and behavioral disturbances are common findings in Parkinson's disease (PD). Despite initially being considered late complications of the disease, it is currently accepted that almost all PD patients will exhibit cognitive and behavioral abnormalities from the early and even the prem...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1629290

    authors: Martinez-Horta S,Horta-Barba A,Kulisevsky J

    更新日期:2019-07-01 00:00:00

  • Pharmacotherapy for social anxiety disorder: a systematic review.

    abstract::Social anxiety disorder (SAD) is a prevalent, disabling disorder. We aimed to assess the effects of pharmacotherapy for SAD and to determine whether particular classes of medication are more effective and/or better tolerated than others. A systematic review and meta-analysis was conducted of all published and unpublis...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.2.235

    authors: Ipser JC,Kariuki CM,Stein DJ

    更新日期:2008-02-01 00:00:00

  • Emotional dysregulation in adult ADHD: What is the empirical evidence?

    abstract::Attention deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder characterized by symptoms of inattention, hyperactivity and impulsivity. There is an ongoing discussion whether symptoms of emotional dysregulation should be added to the conceptualization of ADHD in order to describe the psychopathology ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.109

    authors: Retz W,Stieglitz RD,Corbisiero S,Retz-Junginger P,Rösler M

    更新日期:2012-10-01 00:00:00

  • Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.

    abstract::Alzheimer's disease is common, incurable and disabling. It is expected to grow dramatically in prevalence over the next 50 years. At current, the standard of care for patients with mild and moderately severe Alzheimer's disease includes the use of acetylcholinesterase inhibitors. Donepezil (Aricept) is a highly select...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.1.5

    authors: Geldmacher DS

    更新日期:2004-01-01 00:00:00

  • Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.

    abstract::Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1848548

    authors: Dorfman BJ,Jimenez-Shahed J

    更新日期:2021-01-01 00:00:00